海辰药业股价涨5.77%，华安基金旗下1只基金位居十大流通股东，持有89.03万股浮盈赚取308.04万元

Group 1 - The core point of the news is that Hainan Pharmaceutical Co., Ltd. experienced a stock price increase of 5.77%, reaching 63.38 CNY per share, with a trading volume of 374 million CNY and a turnover rate of 7.63%, resulting in a total market capitalization of 7.606 billion CNY [1] - The company, established on January 15, 2003, and listed on January 12, 2017, focuses on the research, production, and sales of chemical preparations, active pharmaceutical ingredients, and intermediates [1] - The main business revenue composition includes cardiovascular drugs at 87.12%, antibiotics at 5.69%, active pharmaceutical ingredients and intermediates at 1.68%, digestive drugs at 1.50%, antiviral drugs at 1.47%, and other categories [1] Group 2 - Among the top ten circulating shareholders of Hainan Pharmaceutical, a fund under Huaan Fund has entered the list, specifically Huaan Medical Biology Stock Initiation A (022690), holding 890,300 shares, which is 1.08% of the circulating shares [2] - The fund has achieved a year-to-date return of 85.98%, ranking 32 out of 4216 in its category, and has a total scale of 694 million CNY [2] Group 3 - The fund manager of Huaan Medical Biology Stock Initiation A is Sang Xiangyu, who has been in the position for 2 years and 136 days, managing assets totaling 6.379 billion CNY [3] - During his tenure, the best fund return was 89.33%, while the worst return was 11.12% [3]